Skip to Main Content

Author Details

Maria Manczak
Garrison Institute on Aging, Texas Tech University Health Sciences Center
1989
65
41
PMIDPaper TitleJournal TitlePublished Year
34919689A partial reduction of Drp1 improves cognitive behavior and enhances mitophagy, autophagy and dendritic spines in a transgenic Tau mouse model of Alzheimer disease.Hum Mol Genet2022
33639273Protective effects of a mitochondria-targeted small peptide SS31 against hyperglycemia-induced mitochondrial abnormalities in the liver tissues of diabetic mice, Tallyho/JngJ mice.Mitochondrion2021
31595293Protective effects of BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities in Alzheimer's disease.Hum Mol Genet2020
30452626Corrigendum: Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity.Hum Mol Genet2019
30239719Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity.Hum Mol Genet2019
31104030Current Status of Healthy Aging and Dementia Research: A Symposium Summary.J Alzheimers Dis2019
29040533Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer's disease.Hum Mol Genet2018
29701781Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer's disease.Hum Mol Genet2018
29408999Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer's disease.Hum Mol Genet2018
29400667Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer's Disease.J Alzheimers Dis2018
29332042Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease.J Alzheimers Dis2018
28854701Aqua-soluble DDQ reduces the levels of Drp1 and Aβ and inhibits abnormal interactions between Aβ and Drp1 and protects Alzheimer's disease neurons from Aβ- and Drp1-induced mitochondrial and synaptic toxicities.Hum Mol Genet2017
28409745Mitochondria-Division Inhibitor 1 Protects Against Amyloid-β induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease.J Alzheimers Dis2017
28253983MicroRNAs, Aging, Cellular Senescence, and Alzheimer's Disease.Prog Mol Biol Transl Sci2017
28186562Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer's disease.Hum Mol Genet2017
28292876Maternal exercise upregulates mitochondrial gene expression and increases enzyme activity of fetal mouse hearts.Physiol Rep2017
28419260Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer's disease.Hum Mol Genet2017
26908605Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease.Hum Mol Genet2016
28173111Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.Hum Mol Genet2016
27677309Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.Hum Mol Genet2016
27521081Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease.J Investig Med2016
26402018Garrison Institute on Aging: A New Hope for Elderly Individuals and Patients with Alzheimer's Disease.J Alzheimers Dis2015
26464486Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease.Hum Mol Genet2015
23594602Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage.J Alzheimers Dis2013
24063855RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity.Biochim Biophys Acta2013
24055980MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.Biochim Biophys Acta2013
23948905Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies.J Alzheimers Dis2013
22037588Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics.Biochim Biophys Acta2012
23226091Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer's Disease.Pharmaceuticals (Basel)2012
22926141Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.Hum Mol Genet2012
22492996Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.Hum Mol Genet2012
22367970Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage.Hum Mol Genet2012
22387883Dynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficiencies.Biochim Biophys Acta2012
22056405Mitochondrial DNA deletions and differential mitochondrial DNA content in Rhesus monkeys: implications for aging.Biochim Biophys Acta2012
21997870Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.Hum Mol Genet2012
21257639Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.Hum Mol Genet2011
21873260Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease.Hum Mol Genet2011
21741442A transgenic mouse model for Alzheimer's disease has impaired synaptic gain but normal synaptic dynamics.Neurosci Lett2011
21318024Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant SS31.Int J Environ Res Public Health2011
21459773Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage.Hum Mol Genet2011
21145355Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases.Brain Res Rev2011
20413847Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline.J Alzheimers Dis2010
20463406Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons.J Alzheimers Dis2010
19394359Mitochondrial structural and functional dynamics in Huntington's disease.Brain Res Rev2009
19840215Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer's disease and multiple sclerosis.J Neurochem2009
19617638Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.Hum Mol Genet2009
16551656Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression.Hum Mol Genet2006
15659220Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging.J Neurochem2005
16391387Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis.Neuromolecular Med2005
15851848Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction.J Alzheimers Dis2005
  • 1 - 50 of 65

Recommended Authors

University College London, UK Dementia Research Institute
Career Start Year 2013
Number of shared co-authors 0
Seoul National University, College of Medicine
Career Start Year 2012
Number of shared co-authors 0
Tel Aviv University
Career Start Year 2010
Number of shared co-authors 0
Appel Alzheimer's Disease Research Institute
Career Start Year 2008
Number of shared co-authors 0
David Geffen School of Medicine, University of California los angeles
Career Start Year 2007
Number of shared co-authors 0
Institute of Medical Genetics and Applied Genomics, University of Tubingen
Career Start Year 2007
Number of shared co-authors 0
Friedman Brain Institute, Icahn School of Medicine at Mount Sinai
Career Start Year 2005
Number of shared co-authors 0
Vall d'Hebron Research Institute (VHIR)
Career Start Year 2000
Number of shared co-authors 0
University of Manitoba
Career Start Year 2000
Number of shared co-authors 0
Leonard M. Miller School of Medicine, University of Miami
Career Start Year 1999
Number of shared co-authors 0
Helen and Robert Appel Alzheimer's Disease Research Institute
Career Start Year 1999
Number of shared co-authors 0
Center for Bionano Intelligence Education and Research, Hanyang University
Career Start Year 1995
Number of shared co-authors 0
Brain and Mind Research Institute
Career Start Year 1991
Number of shared co-authors 1
Buck Institute for Research on Aging
Career Start Year 1990
Number of shared co-authors 0
Baylor College of Medicine
Career Start Year 1989
Number of shared co-authors 0
J. David Gladstone Institutes
Career Start Year 1988
Number of shared co-authors 0
Stanford University
Career Start Year 1988
Number of shared co-authors 4
Institute for Cell Engineering, Johns Hopkins University School of Medicine
Career Start Year 1988
Number of shared co-authors 1
Tufts Medical Center and Neuroscience, Tufts University
Career Start Year 1987
Number of shared co-authors 3
National Institute On Aging
Career Start Year 1986
Number of shared co-authors 3
University of Brescia
Career Start Year 1985
Number of shared co-authors 0
Johns Hopkins University School of Medicine
Career Start Year 1983
Number of shared co-authors 1
University of Kentucky
Career Start Year 1982
Number of shared co-authors 2
Georgetown University
Career Start Year 1981
Number of shared co-authors 3
German Center for Neurodegenerative Diseases (DZNE) Munich
Career Start Year 1981
Number of shared co-authors 0
Icahn School of Medicine at Mount Sinai
Career Start Year 1980
Number of shared co-authors 0
Inc. University Avenue
Career Start Year 1980
Number of shared co-authors 1
Massachusetts General Hospital
Career Start Year 1977
Number of shared co-authors 3
Perelman School of Medicine at the University of Pennsylvania
Career Start Year 1977
Number of shared co-authors 3
College of Sciences, The University of Texas at San Antonio
Career Start Year 1970
Number of shared co-authors 0

Collaborators

Texas Tech University Health Sciences Center
Co-authored papers 51
Oregon Health & Science University
Co-authored papers 9
Department of Neurology Mayo Clinic Rochester Minnesota.
Co-authored papers 3
Neurological Sciences Institute, Oregon Health and Science University
Co-authored papers 2
Oregon Health and Science University
Co-authored papers 2
Brigham and Women's Hospital
Co-authored papers 1
Oregon Center for Aging & Technology
Co-authored papers 1
Oregon Health & Science University
Co-authored papers 1
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Co-authored papers 1
St Jude Children's Research Hospital.
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Indian Institute of Technology Delhi
Co-authored papers 1
University of Cambridge
Co-authored papers 1
University of Kansas Alzheimer's Disease Research Centre
Co-authored papers 1
University of Washington School of Medicine, and NovaBay Pharmaceuticals
Co-authored papers 1